TICKERNERD
Menu
GDRXGDRXHealthcare · Health Information Services

GDRX Stock Forecast: GoodRx Holdings, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$3.72
+6.59% on the day

The 14 Wall Street analysts covering GoodRx Holdings, Inc. hold a median 12-month price target of $4 — +7.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.2B
Ticker Nerd rank
80/ 100
Median analyst target
$4.00
Analysts covering
14
Revenue$200.4M−1.3% y/y
Operating income$23.6M
Net income$8.5M
Free cash flow$66.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+7.2%
1M
+13.4%
YTD
+37.3%
1Y
+14.1%
From 52W high
−2.1%
From 52W low
+98.9%
$1.87
$3.80
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GDRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores GoodRx Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
80/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
92
Issuance
92
Accruals
77
Quality
74
Volatility
71
Revisions
57
Momentum
56
Size
41
Growth
18

Value (92): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GDRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GDRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26GDRXHigh $5.00Median $4.00Low $2.65

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
4 Buy8 Hold2 Sell
Low $2.65Median $4.00High $5.00

The green dot is the last close — the median target sits +7.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
21 Aug 2026BarclaysMaintainsUnderweight$3.00 → $4.00
13 Aug 2026UBSMaintainsNeutral—
13 Aug 2026UBSMaintainsNeutral$2.50 → $3.75
11 Aug 2026CitigroupMaintainsBuy—
11 Aug 2026CitigroupMaintainsBuy$4.00 → $5.00
11 Aug 2026TD CowenMaintainsBuy$4.00 → $5.00
11 Aug 2026TD CowenMaintainsBuy—
7 Aug 2026Wells FargoMaintainsOverweight—
7 Aug 2026Wells FargoMaintainsOverweight$3.50 → $5.00
14 May 2026CitigroupMaintainsBuy—
14 May 2026CitigroupMaintainsBuy$3.50 → $4.00
11 May 2026TD CowenMaintainsBuy$3.00 → $4.00
11 May 2026TD CowenMaintainsBuy—
4 Mar 2026Wells FargoMaintainsOverweight—
3 Mar 2026CitigroupMaintainsBuy—
2 Mar 2026Goldman SachsMaintainsNeutral—
27 Feb 2026JP MorganDowngradeNeutral—
27 Feb 2026MizuhoMaintainsNeutral—
22 Jan 2026JefferiesDowngradeHold—
9 Jan 2026CitigroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

GDRX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

GDRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, GoodRx Holdings, Inc. returned +14.1% against +14.8% for the S&P 500, dividends included.

GDRX vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26GDRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GDRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−1.9%
Analysts raising
4
Analysts cutting
5
Fundamentals

GoodRx Holdings, Inc. (GDRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
70.1×

Cheaper than 10% of US stocks

Price / sales
1.5×

Cheaper than 58% of US stocks

Price / book
1.8×

Cheaper than 46% of US stocks

EV / EBITDA
13.4×

Cheaper than 27% of US stocks

Growth & margins
Revenue growth (YoY)
−1.3%

Higher than 25% of US stocks

Earnings growth (YoY)
−33.5%

Higher than 15% of US stocks

Gross margin
89.5%

Higher than 96% of US stocks

Operating margin
11.8%

Higher than 67% of US stocks

Net margin
2.1%

Higher than 52% of US stocks

Returns & dividend
Return on equity
2.5%

Higher than 49% of US stocks

Return on assets
3.0%

Higher than 65% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

GoodRx Holdings, Inc. (GDRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • GoodRx Holdings, Inc. has a market value of $1.2B and an enterprise value of $1.5B.

  • Revenue in the twelve months to 30 June 2026: $785.2M. The latest quarter shrank 1.3% year on year.

  • Net income over the same four quarters: $16.2M, a 2.1% net margin.

  • Diluted earnings per share, trailing twelve months: $0.05.

  • Free cash flow in the twelve months to 30 June 2026: $131.7M, after $65.4M of capital spending.

  • GoodRx Holdings, Inc. spent $85.0M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 340.1M.

  • Trailing P/E: 70.1×; forward P/E: 10.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • GoodRx Holdings, Inc. employs 697 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

GDRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
GDRXGoodRx Holdings, Inc.$1.2B80
OMDAOmada Health, Inc.$1.1B80
HSTMHealthStream, Inc.$963.6M92
TDOCTeladoc Health, Inc.$1.7B86
CERTCertara, Inc.$1.8B65
OMCLOmnicell, Inc.$1.8B98
PHRPhreesia, Inc.$794.6M54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own GoodRx Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GDRX news & analysis

GoodRx Holdings Is Going Through A Painful Transition That Will Pay Off

Seeking Alpha · 31 Oct 2026neutral

Seeking Alpha says GoodRx faced 2026 declines amid falling monthly active users and retail pharmacy disruptions, following revenue and profit growth through 2025. Investments in subscriptions and Pharma Direct, including weight loss drugs, are supporting growth in new segments while pressuring margins.

Why it matters — The combination of operating headwinds and investment in newer growth areas may shape GoodRx’s performance and margins.

GoodRx Launches Employer Direct Weight Loss Offering

Business Wire · 29 Oct 2026positive

GoodRx announced the market-wide launch of its Employer Direct weight loss offering, which lets employers help employees access and afford FDA-approved GLP-1 medications. The offering is designed to provide access outside the traditional pharmacy benefit.

Why it matters — GDRX watchers may note the launch as an expansion of GoodRx’s employer-focused offerings for access to weight loss medications.

Amazon, GoodRx target US prescription subscribers as health insurance coverage slips

Reuters · 29 Sept 2026positive

Reuters reports that Amazon, GoodRx and other companies offering flat-fee online subscriptions for prescription drugs and health services are benefiting from Americans seeking relief from rising healthcare costs and fewer health insurance options.

Why it matters — For GDRX watchers, this indicates growing demand for GoodRx's subscription offerings as health insurance coverage declines, potentially expanding its customer base.

GoodRx Covers Whole Households and Pets in New Prescription Plan

PYMNTS · 4 Sept 2026positive

GoodRx has launched a new prescription plan covering a primary member and up to four dependents, including children, adult family members, and pets, according to a Sept. 3 press release.

Why it matters — This expansion widens GoodRx's potential customer base and could increase its reach within households, which is relevant to its growth outlook.

GoodRx offers health subscription for families, to launch as employee benefit in 2027

Reuters · 3 Sept 2026positive

GoodRx announced a family healthcare subscription providing access to common medical services and over 250 medications, with plans to launch the program as part of employer health benefits in 2027.

Why it matters — A GDRX watcher would care because this new subscription and planned employer-benefit rollout could expand GoodRx's reach and revenue streams beyond its existing prescription savings model.

FAQ

Frequently asked questions about GDRX stock

What is the GDRX stock price forecast for 2026-2027?

The 14 Wall Street analysts covering GoodRx Holdings, Inc. have a median 12-month price target of $4, with estimates ranging from $2.65 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GDRX stock a buy right now?

Of the 14 analysts covering GoodRx Holdings, Inc., 4 rate it a Buy, 8 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks GoodRx Holdings, Inc. 80 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GDRX?

As at 4 Nov 2026, GoodRx Holdings, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (92 of 100).

Will GDRX stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +7.5% from the last close, and Ticker Nerd's factor model ranks GoodRx Holdings, Inc. 80 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GDRX stock forecast for 2030?

No analyst covering GoodRx Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GDRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.65 to $5 over the next 12 months.

How has GDRX stock performed over the past year?

GoodRx Holdings, Inc. returned +14.1% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does GoodRx Holdings, Inc. do?

GoodRx Holdings, Inc. Class A Common Stock represents ownership in GoodRx, a consumer-focused digital healthcare company that helps U.S.

What is the latest news on GDRX?

The most recent item we track (Seeking Alpha, 31 Oct 2026): "GoodRx Holdings Is Going Through A Painful Transition That Will Pay Off". Seeking Alpha says GoodRx faced 2026 declines amid falling monthly active users and retail pharmacy disruptions, following revenue and profit growth through 2025. Investments in subscriptions and Pharma Direct, including weight loss drugs, are supporting growth in new segments while pressuring margins.

Company

About GoodRx Holdings, Inc.

GoodRx Holdings, Inc. Class A Common Stock represents ownership in GoodRx, a consumer-focused digital healthcare company that helps U.S. consumers compare prescription drug prices and access savings tools. GoodRx provides a price comparison platform with geographically relevant pharmacy pricing, discount codes, and prescription transaction services designed to make medication costs more transparent. The company also offers telehealth services, subscription products, and pharma manufacturer solutions that support patients, pharmacies, healthcare professionals, payers, and pharmaceutical partners. Its platform is used across the prescription marketplace to connect users with retail pharmacies and medication savings resources. Headquartered in Santa Monica, California, GoodRx operates primarily in the U.S. healthcare market, where it plays a role in digital prescription savings, healthcare information, and patient access services.

CEO Ms. Wendy Barnes · 697 employees · United States · https://www.goodrx.com